Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

COVID-HIGIV · NP-028

Plasma-derived product · Immune activation, directed at SARS-CoV-2 spike protein · developed by Emergent BioSolutions

Phase 1 Most advanced trial (none active)
EBS Developer
1 Registered trials

What is COVID-HIGIV?

COVID-HIGIV is a purified immunoglobulin G preparation containing neutralizing antibodies to SARS-CoV-2, administered intravenously for COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NP-028
Drug type
Plasma-derived product
Targets
SARS-CoV-2 spike protein
Mechanism
Immune activation, directed at SARS-CoV-2 spike protein
Therapy area
Infectious disease
Developer
Emergent BioSolutions (EBS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04661839 Phase 1 COVID-19 Completed EBS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COVID-19

More from Emergent BioSolutions

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the EBS page.

Follow EBS, the company behind COVID-HIGIV

See EBS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EBS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.